Goldspan Health sits at No. 78 in our ranking with a Brief Score of 76. Here are the GLP-1 providers we'd weigh against it — ranked on the same six-factor Brief Score, top down.
Prefer a straight head-to-head? CoreAge Rx vs Goldspan Health.
One price on both molecules that does not climb as you titrate — but the headline $99 and $149 are annual-plan rates, paid in full up front.
REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.
A newer (2024) compounding provider whose real hook is form: it runs an oral/sublingual line alongside the usual injections, on both molecules, with no membership tacked on.
FDA warning letter, September 2025 — issued to directmeds.com, Inc. dba DirectMeds. See the FDA's warning letter database.
Fitish offers compounded semaglutide ($219/28 days) and compounded tirzepatide ($339/28 days) including consultation and shipping.
FDA warning letter, June 2026 — issued to FITISH. See the FDA's warning letter database.
A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.
Identical $199 pricing on both molecules, an oral route, LegitScript-certified and nationwide.
FDA warning letter, September 2025 — issued to Curex. See the FDA's warning letter database.
An all-in, LegitScript-verified GLP-1 line with a simple sticker price — billed every 4 weeks rather than by the calendar month, and with no named prescriber or pharmacy behind it.
Tru2u is a US direct-to-consumer telehealth and wellness store offering provider-guided compounded GLP-1 weight-loss therapy alongside hair, skincare, and supplement lines.
Rankings reflect the Dose Brief Score — our editorial judgment per the methodology. Pricing and coverage reflect public disclosures at last review and change often — confirm on each provider's site. Not medical advice; see our disclosure.